A machine learning model for predicting blood concentration of quetiapine in patients with schizophrenia and depression based on real-world data
- PMID: 37005382
- DOI: 10.1111/bcp.15734
A machine learning model for predicting blood concentration of quetiapine in patients with schizophrenia and depression based on real-world data
Abstract
Aims: This study aimed to establish a prediction model of quetiapine concentration in patients with schizophrenia and depression, based on real-world data via machine learning techniques to assist clinical regimen decisions.
Methods: A total of 650 cases of quetiapine therapeutic drug monitoring (TDM) data from 483 patients at the First Hospital of Hebei Medical University from 1 November 2019 to 31 August 2022 were included in the study. Univariate analysis and sequential forward selection (SFS) were implemented to screen the important variables influencing quetiapine TDM. After 10-fold cross validation, the algorithm with the optimal model performance was selected for predicting quetiapine TDM among nine models. SHapley Additive exPlanation was applied for model interpretation.
Results: Four variables (daily dose of quetiapine, type of mental illness, sex and CYP2D6 competitive substrates) were selected through univariate analysis (P < .05) and SFS to establish the models. The CatBoost algorithm with the best predictive ability (mean [SD] R2 = 0.63 ± 0.02, RMSE = 137.39 ± 10.56, MAE = 103.24 ± 7.23) was chosen for predicting quetiapine TDM among nine models. The mean (SD) accuracy of the predicted TDM within ±30% of the actual TDM was 49.46 ± 3.00%, and that of the recommended therapeutic range (200-750 ng mL-1 ) was 73.54 ± 8.3%. Compared with the PBPK model in a previous study, the CatBoost model shows slightly higher accuracy within ±100% of the actual value.
Conclusions: This work is the first real-world study to predict the blood concentration of quetiapine in patients with schizophrenia and depression using artificial intelligent techniques, which is of significance and value for clinical medication guidance.
Keywords: CatBoost; artificial intelligent technique; blood concentration prediction; machine learning; quetiapine.
© 2023 The British Pharmacological Society.
References
REFERENCES
-
- Cheer SM, Wagstaff AJ. Quetiapine. A review of its use in the management of schizophrenia. CNS Drugs. 2004;18(3):173-199. doi:10.2165/00023210-200418030-00004 PMID: 14871161
-
- Quetiapine indications: FDA-approved and off-label uses; 2020. https://psychopharmacologyinstitute.com/publication/quetiapine-indicatio.... Accessed April 9, 2023.
-
- Spina E, de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol. 2007;100(1):4-22. doi:10.1111/j.1742-7843.2007.00017.x
-
- Burns K, Helsby NA. Cytochrome P450 in GtoPdb v.2021.2. IUPHAR/BPS Guide to Pharmacology CITE. 2021;2021(2). doi:10.2218/gtopdb/F242/2021.2
-
- Kasper S, Müller-Spahn F. Review of quetiapine and its clinical applications in schizophrenia. Expert Opin Pharmacother. 2000;1(4):783-801. doi:10.1517/14656566.1.4.783
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
